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Abstract. – OBJECTIVE: Surgical site infec-
tions (SSIs) are the third most common hospi-
tal-acquired infections and account for 14% to 
16% of all such infections, and suture material 
may play a role in SSI rate. Given this risk of in-
fection, sutures with antimicrobial activity have 
been developed. Both in vitro and in vivo experi-
ments have shown that triclosan-coated sutures 
(TCS) are effective in the prevention of SSIs. Our 
aim is to analyze currently available RCTs, com-
paring the effect of antimicrobial-coated suture 
(ACS) with uncoated suture on the occurrence 
of SSIs following surgical procedures, we high-
lighted major contributions of most significant 
studies and evaluate the current “state of the 
art” on antimicrobial-coated sutures.
MATERIALS AND METHODS: We reviewed 
15 RCTs comparing antimicrobial-coated sutures 
with conventional sutures and assessing the clin-
ical effectiveness of antimicrobial sutures to de-
crease the risk for SSIs. We focused our attention 
on each variable in all the analyzed study. 
RESULTS: Our selected RCTs, produced con-
troversial results: 7 RCTs demonstrated a signif-
icant benefit, on the contrary, 8 RCTs presented 
a comparison in which there was no difference.
CONCLUSIONS: On the basis of our select-
ed trial results and the heterogeneous find-
ings of our 7 selected meta-analyses, we con-
clude that even though the question of wheth-
er TCSs could reduce the occurrence of SSI re-
mains still open, the antimicrobial suture was ef-
fective in decreasing the risk for postoperative 
SSIs in a broad population of patients undergo-
ing surgery. Alternative substances are becom-
ing clinically relevant, such as Chlorhexidine 
(CHX) coated sutures and only 6 in vivo scientif-
ic studies evaluated them. In vivo studies, large 
and comparative clinical research trials are nec-
essary to validate the efficacy of CHX-coated su-
tures thus allowing their use in clinical practice.
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Introduction
Wound infections after surgery are still fre-
quent types of nosocomial infections, and poor 
healing continues to be among the most com-
plications after surgery too. Despite established 
systemic antibiotic prophylaxis, surgical site in-
fections (SSIs) are the third most common hos-
pital-acquired infections in the United States, 
accounting for 14%e16% of infections among 
hospitalized patients and 38% of infections in 
surgical patients1,2.
In European countries, the estimated SSI in-
cidence range varies from 1,5% to 20%, due to 
differences among studies regarding how surgical 
procedures are conducted and how SSI data are 
collected3. However, the true rate of SSI is be-
lieved to be underestimated, indicating that SSIs 
represent a significant problem in Europe as well.
The most widely recognized definition of in-
fection, which is used throughout the United 
States and Europe, is that devised and adopted 
by the Centres for Disease Control (CDC) and 
Prevention4,5. SSI is defined as an infection within 
30 days of surgery (or within a year in case of 
prosthetic surgery). 
Suture material is an operator-dependent vari-
able, and while little objective data exist to guide 
the choice of suture, it may play an important role 
in the development of SSIs by providing a local 
surface for the adherence of microorganisms6-8.
Because of this risk of infection, the strategy 
of coating sutures with antimicrobial activity has 
been considered, with the attempt to avoid bac-
terial colonization of medical materials from the 
beginning9. In 2002, the US Food and Drug Ad-
ministration approved the first antimicrobial sur-
gical suture (braided polyglactin 910, Vicryl Plus) 
coated with triclosan (polychlorophenoxyphenol), 
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a biocide that exhibits broad-spectrum activity 
against both Gram-positive and Gram-negative 
bacteria. Several scientific studies well-described 
the rationale for assuming that the use of suture 
impregnated with triclosan may reduce the oc-
currence of SSI, showing a series of robust data 
obtained by in vitro and in vivo experiments10-20.
On the contrary, some clinical trials have sug-
gested that coating sutures with triclosan do not 
reduce the risk of SSI21-28.
Our aim was to analyze currently available 
Randomized Clinical Trials (RCTs), comparing 
the effect of the antimicrobial-coated suture with 
the uncoated suture on the incidence of SSIs 
following surgical procedures in order to provide 
a comprehensive assessment of the available ev-
idence. We highlighted major contributions of 
most significant studies and evaluate the current 
“state of the art” on suture materials.
Materials and Methods
We performed a revision of the peer-reviewed 
international literature on PubMed, Embase/Med-
line, Scopus, Ovid, ISI Web of Science, Cochrane 
database group (Central Register of Controlled 
Trials, Cochrane Database of Systematic Reviews, 
Health Economic Evaluations Database/Database 
of Health Technology Assessments) and www.
clinicaltrials.gov to identify Clinical Trial of anti-
microbial-coated sutures compared with conven-
tional sutures, and to assess the clinical effective-
ness of antimicrobial sutures to decrease the risk 
for SSIs, the last search updated on April 2017. 
The search strategy was personalized around 
specific key-words and combinations of these: 
“uncoated suture”, “coated suture”, “antimicrobi-
al”, “antiseptic”, “suture”, “triclosan”, “infection”, 
“surgical site infection” and “surgical wound in-
fection”. In case of overlap of authors, affiliations, 
or patients, we chose the most recent article.
Inclusion Criteria
We included only RCTs with pediatric and 
adult patients comparing the clinical efficacy of 
triclosan-coated sutures with traditional uncoated 
sutures in reducing SSI prevalence, for surgical 
procedures.
Exclusion Criteria
We did not include in vitro experiments, ani-
mal studies, non-randomized controlled trials, pi-
lot studies, studies not statistically analyzing the 
obtained results, abstracts, unpublished studies, 
letters to Editor, editorials, opinion pieces and 
finally Conference proceedings.
Data Extraction
 Data taken into account were as follows: first 
author/year/country, clinical sample size, study 
design blinding and follow-up length, whether 
SSI was defined according to CDC criteria, clin-
ical indication and surgical procedures, suture 
material, outcome/infection (prevalence of SSI), 
number of patients and events (SSIs).
Study Quality 
The Cochrane Collaborative Evidence-Based 
handbook formed the basis for or analysis, iden-
tifying all relevant clinical studies.
Results
Flow diagram (Figure 1) showed the literature 
search and article selection. Records identified 
through database searching were 407. We removed 
the duplicates (98) and identified 27 potentially 
relevant citations through the electronic searches. 
Records screened were 336 RCTs, of them 114 
were the RCTs assessed for the eligibility. 
We identified 15 peer-reviewed eligible RCTs 
comparing triclosan-coated sutures (Study Group, 
SG) with uncoated sutures (Control Group, CG). 
The sample size of included RCTs ranged 
from 84 to 1185 participants.
Of the studies, 10 were single-centre tri-
als14,15,17-21,23,27,28 whereas 5 were multicentre tri-
als16,22,24-26 . Follow-up ranged from 4 weeks days 
to 24 months, with most studies reporting out-
comes at 30 days in accordance with CDC crite-
ria16,18-20,22-26,28.
Eight RCTs15,17-19,21,22,24,26 involved abdominal 
surgeries (1 open appendicectomy21, 3 laparoto-
my15,19,22 for various abdominal operations, 4 col-
orectal surgery17,18,24,26), two RCTs regarded cardi-
ac surgeries27,28, two regarded peripheral vascular 
surgery20,25, one RCT concerned breast surgery23, 
and two RCTs14,16 referred to other surgeries. De-
tailed characteristics of the included studies are sum-
marized in Table I. Eight trials14,16-18,21,26-28 compared 
triclosan-coated Polyglactin (Vicryl Plus) sutures 
with uncoated Polyglactin (Vicryl) sutures, three tri-
als19,22,24 compared triclosan-coated Polydioxanone 
(PDS) sutures with uncoated Polydioxanone (PDS 
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II) sutures, three trials20,23,25 compared two types 
of triclosan-coated (Vicryl plus, Monocryl plus) 
sutures with the corresponding uncoated sutures. 
One trial25 compared two types of triclosan-coated 
Polyglactin/Polydioxanone (Vicryl plus/PDS plus) 
sutures with the corresponding uncoated silk su-
tures. Finally, one trial15 compared triclosan-coated 
Polyglactin (Vicryl Plus) sutures with uncoated 
Polydioxanone (PDS II) and Silk sutures.
Our selected RCTs produced controversial 
results. 7 RCTs14-20 demonstrated a significant 
benefit, on the contrary, 8 RCTs21-28 presented a 
comparison in which there is no difference.
Discussion 
The potential reasons for disagreement among 
study results are the clinical sample size, dif-
ferent study designs, blindness of patients and 
assessors, length of follow-up, heterogeneity of 
surgical procedures, methods, definition of SSI, 
evaluation of risk factors in the analysis, inclu-
sion and exclusion criteria, suture material used, 
parameters evaluated, and unrecorded data at 
follow-up. 
We analyzed in details each variable, respon-
sible of heterogeneity among the studies. 
Figure 1. Flow-chart: literature serch and article (randomized clinical trials, RCTs, and meta-analyses).
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Authors/year/ Sample Size Design of randomized Surgical Comparator Conclusions Statistical
 country  (SG vs. CG)  control trial/   procedures  suture  ACS (SG, infected  Analysis
   adherence to CDC   material:  patients%) vs.  Conclusion
   criteria/Length   ACS vs. NAS   NAS (CG, infected
   of follow-up    patients%)
    
Rozelle14/ 84 (46 SG Single-centre trial,  Paediatric/adult,  Triclosan-coated ACS 2/46 (4.3%) vs.  Reported lowest rate
 2008/ USA  vs. 38 CG)  prospective, double-  cerebrospinal Polyglactin (Vicryl plus)   NAS 8/38 (21.1%)  in Triclosan-coated
   blinded, and placebo-  shunt surgery  suture vs. uncoated Triclosan-coated  sutures
   controlled study  Polyglactin (Vicryl)   suture reduced risk Reduction
  CDC not specified    suture  of postoperative
  6-months follow-up     shunt infection
Mingmalairak21/ 100 (50 SG Single-centre trial,  Adult, open Triclosan-coated ACS 5/50 % (10%) vs.  There was no statistical
 2009/ Thailand  vs. 50 CG)  prospective, double  appendicectomy  Polyglactin (Vicryl Plus)  NAS 4/50 (8%)  difference in the SSI of
   blinded   suture vs. uncoated SSI of appendectomy  triclosan-coated and
  CDC not specified  Polyglactin (Vicryl)   seemed to be comparable  uncoated sutures
  12-months follow-up    suture  between triclosan- No difference
      coated suture and 
      uncoated suture.
Zhuang15/2009/ 450 (150 SG vs. Single-centre trial,   Adult, laparotomy Triclosan-coated ACS (Polyglactin)  Reported lowest rate in
 China  300 CG)  prospective, assessor-  for various Polyglactin (Vicryl Plus)   0/150 (0%) vs.  triclosan-coated sutures 
   blinded  abdominal  suture vs. Polydioxanone/  NAS (Polydioxanone) Reduction
  CDC not specified  operations  Silk suture  3/150 (0.02%)
  12-24 months follow-up   NAS (Silk) 15/150 (0.1%)
Williams23/2011/ 127 (66 SG vs.  Single-centre trial,  Adult, breast cancer Triclosan coated ACS 10/66 (15.2%) vs.  The difference was not
 UK  61 CG)  prospective, double-  surgery  (Vicryl plus, Monocryl  NAS 14/61 (22.9%)   statistically significant
   blinded   plus) sutures vs. (Vicryl,  This trial failed to   between the groups.
  CDC   Monocryl) uncoated-  find a difference No difference 
  6-weeks follow-up    sutures
Rasic17/2011/ 184 (91 SG vs.  Single-centre trial,  Adult, colorectal Triclosan-coated Polyglactin ACS 4/91 (4.4%) vs.  Statistically significant
 Croatia  93 CG)  prospective, not blinded,  surgery  (Vicryl Plus) suture vs.  NAS 12/93 (12.9%)  difference between
   CDC not specified   uncoated Polyglactin Abdominal closure with an  the groups
  Follow-up (unspecified,    (Vicryl) suture  ACS was associated with Reduction
   apparently, minimum     a decrease in SSI compared 
   14 days)    to uncoated sutures.  
Seim27/2012/ 323 (SG 160 vs.  Single-centre trial,  Adult, cardiac Triclosan-coated-Polyglactin ACS 16/160 (10%) vs.  There were no significant
 Norway  163 CG)  prospective, not blinded  surgery  suture (Vicryl Plus) vs.   NAS 17/163 (10.4%)  differences between the
  CDC no specified   uncoated Polyglactin Vicryl Plus did not reduce  two study groups.
  4 weeks follow-up   (Vicryl) suture  the occurrence of leg No difference
      wound infections
Table I. Randomized control trials comparing the effect of antimicrobial-coated suture with uncoated suture on occurrence of surgical site infections following surgical procedures.
Continued
5733
Authors/year/ Sample Size Design of randomized Surgical Comparator Conclusions Statistical
 country  (SG vs. CG)  control trial/   procedures  suture  ACS (SG, infected  Analysis
   adherence to CDC   material:  patients%) vs.  Conclusion
   criteria/ Length   ACS vs. NAS   NAS (CG, infected
   of follow-up    patients%)
    
 Isik28/2012/ 510 (170 SG vs.  Single-centre trial, Adult, cardiac Triclosan coated Polyglactin ACS 4/170 (2.3%) vs.  No statistically significant
 Turkey  340 CG)   prospective, double-  surgery  (Vicryl plus) suture vs.  NAS 12/340 (3.5%)  difference between
   blinded   (Vicryl) uncoated  Larger studies may be  the groups
  CDC   Polyglactin suture  needed to show the No difference
  30 days follow-up    benefit and cost-
      effectiveness, if any,
      of triclosan-coated 
      materials over 
      uncoated materials.  
Nakamura18/2013/ 410 (206 SG vs. Single-centre trial, prospec- Adult, colorectal Triclosan-coated Poly- ACS 9/206 (4.3%) vs. Statistically significant
 Japan  204 CG)  tive, double-blinded  surgery  glactin 910 (Vicryl plus)  NAS 19/204 (9.3%)  difference between
   CDC   suture vs. (Vicryl) uncoated Triclosan-coated sutures  the groups.
  30 days follow-up  Polyglactin 910 suture  can reduce the occurrence  Reduction
      of wound infections 
      in colorectal surgery.
Justinger19/2013/ 856 (SG 485 vs.  Single-centre trial,  Laparotomy for Triclosan-coated Polydio- ACS 31/485 (6.4%) vs.  Statistically significant
 Germany  371 CG)   prospective, double- general and  xanone loop (PDS plus)  NAS 42/371 (11.3%)  difference
   blinded  abdominal vascular  suture vs. uncoated Triclosan impregnation of Reduction
  CDC procedures Polydioxanone loop  Polydioxanone closing 
  2-weeks follow-up   (PDS II) suture  suture can decrease wound 
      infections. 
Thimour- 371 (184 SG vs. Single-centre, prospective,  Leg incision after Triclosan coated Polyglactin/ ACS 23/184 (12.5%) vs. The difference was
 Bergstom20/2013/  190 CG)  double- blinded  vein harvesting  Polydioxanone (Vicryl plus/  NAS 38/190 (20%)  statistically significant
 Sweden  CDC  for CABG Monocryl plus) suture vs. Leg-wound closure with Reduction
  60 days follow-up   uncoated-coated Polyglactin/  triclosan-coated sutures 
     Polydioxanone (Vicryl,  in CABG patients reduces
     Monocryl) suture  SSIs after open vein 
      harvesting.
Galal16/2011/ 450 (230 SG vs. Multicentre trial, prospective Adult, general  Triclosan-coated Polyglactin ACS 17/230 (7.4%) vs.  The difference was
 Egypt 220 CG)  double-blinded  surgery (78%),   910 (Vicryl plus) suture vs. NAS 33/220 (15%)  statistically significant
  CDC  plastic surgery (19%),  uncoated Polyglactin 910  triclosan-coated sutures Reduction
  30 days follow-up; 1 year   other (3%)  (Vicryl) suture  lead to reduction of
   if prosthesis    surgical site infection
Table I. Randomized control trials comparing the effect of antimicrobial-coated suture with uncoated suture on occurrence of surgical site infections following surgical procedures.
Continued
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Authors/year/ Sample Size Design of randomized Surgical Comparator Conclusions Statistical
 country  (SG vs. CG)  control trial/   procedures  suture  ACS (SG, infected  Analysis
   adherence to CDC   material:  patients%) vs.  Conclusion
   criteria/Length   ACS vs. NAS   NAS (CG, infected
   of follow-up    patients%)
    
Baracs24/2011/ 385 (188 SG vs.  Multicentre trial,  Adult, colorectal Triclosan-coated ACS 23/188 (12.2%) vs.  No significant difference
 Hungary  197 CG)  prospective, not blinded  surgery Polydioxanone (PDS plus)  NAS 24/197 (12.2%)  between the groups
  CDC  suture vs. uncoated  No difference
  30-days follow-up   Polydioxanone (PDSII)
     suture 
Turtainen25/2012/ 276 (139 SG vs.  Multicentre trial,  Adult, peripheral Triclosan-coated Polyglactin ACS 31/139 (22.5%) vs.   There was no statistically
 Finland  137 CG)  prospective, double-  vascular surgery  or Poliglecaprone (Vicryl  NAS 30/137 (21.9%)  significant difference
   blinded   plus, Monocryl plus) Triclosan-coated suture does  between the triclosan
  CDC   suture vs. uncoated  not reduce the occurrence  group and the control
  1-month follow-up   Polyglactin or Poligle-  of SSI n after lower limb  group in the occurrence
     caprone (Vicryl, Monocryl)  vascular surgery  of SSI.
     suture  No difference 
     
Diener22/2014/ 1185 (587 SG vs.  Multicentre trial, prospective,  Adult, elective Triclosan-coated Polydio- ACS 87/587 (14.8%) vs.  The difference was not
 Germany   598 CG)  patients surgeons and  midline laparotomy  xanone (PDS Plus) suture  NAS 96/598 (16.1%)  statistically significant
   outcome assessors blinded  (abdominal surgery)  vs. uncoated Polydioxanone The occurrence of surgical No difference
  CDC   (PDS II) suture  site infections did not differ 
  30 days follow-up    between the PDS Plus and 
      the PDS II group.   
      
Mattavelli26/2015/ 281 (SG 140 vs. Multicentre trial, patients Adult, colorectal Polyglactin 910 triclosan- ACS 18/140 (12.9%)  This trial failed to
 Italy  141 CG)  and outcome assessors-  surgery  coated suture (Vicryl plus)  vs. NAS 15/141 (10.6%)  demonstrate a protective
   blinded   vs. Polyglactin 910 (Vicryl) Surgical sutures triclosan-  effect of triclosan-coated
  CDC   uncoated suture  coated do not appear to  sutures on the occurrence
  30 days follow-up    be effective in reducing  of SSI
      the rate of SSI. No difference
Table I. Randomized control trials comparing the effect of antimicrobial-coated suture with uncoated suture on occurrence of surgical site infections following surgical procedures.
SG: Study Group; CG: Control Group; vs.:Versus; ACS: Antimicrobial-coated sutures; NAS: Non-Antimicrobial Sutures. CABG: Coronary Artery Bypass Grafting.
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As upon described, the sample size of includ-
ed RCTs ranged from 84 to 1185 participants.
If we focused our attention on the clinical trial 
with the lowest number of participants, we can note 
that Rozzelle et al14 included in their comparative 
study, 84 participants and concluded that TCSs re-
duced the risk of postoperative shunt infection. The 
sample size in this study was far too small, and thus 
it was underpowered to draw any conclusions on the 
effect of TCSs on the risk of SII.
Of the studies, 10 were single-centre tri-
als14,15,17-21,23,27,28 whereas 5 were multicentre trials 
16,22,24-26.
Our findings showed that in 6 single-center 
studies14,15,17-20 and only in 1 multicentre study16, 
TCS was superior to uncoated one in reducing SSI. 
It is obvious that when TCS is introduced as a sin-
gle variable in a homogenous and uniform back-
ground, the effect is more evident. On the contrary, 
multicentre studies are characterized by numerous 
variables affecting results, a situation more similar 
to realty, and if in this setting a new treatment 
is truly effective, it should stand the challenge 
of multifactorial events. In the light of this con-
cept, we analyzed the unique selected multicentre 
study, confirming the protective effect of TCSs on 
SSIs16. Authors16 performed a prospective, random-
ized, double-blinded, controlled multicentre study 
aimed to compare triclosan-coated polyglactin 910 
sutures with polyglactin 910 sutures for the reduc-
tion of SSI. Authors’ conclusion specified that the 
use of the TCS leads to a reduction of SSI. Article 
limitations are related to heterogeneity of study 
population of surgical patients (vascular surgery, 
plastic surgery, gastrointestinal surgery, thyroidec-
tomy, lipoma removal). Moreover, some methods 
such as the closing of the surgical incision together 
with the type of antibiotic prophylaxis were not 
standardized. Furthermore, they conducted a mul-
ticentre study but reported the results of a single 
center only.
In our research, follow-up ranged from 4 
weeks days to 24 months, with most studies re-
porting outcomes at 30 days in accordance with 
CDC criteria16,18-20,22-26,28. 
It is fundamental, that a clinical trial used 
CDC Criteria in defining SSIs, such that asses-
sors follow a standard protocol for identifying 
SSIs. Among a group of RCTs, when a trial did 
not adhere to these criteria, it may introduce 
clinical heterogeneity.
In our findings, Seven RCTs17-19,21,22,24,26 in-
volved abdominal surgeries (1 open appendi-
cectomy21, 2 elective laparotomy19,22, 4 colorec-
tal surgery17,18,24,26), two RCTs regarded cardiac 
surgeries27,28, two concerned peripheral vascular 
surgery20,25, one RCT regarded breast surgery23, 
and finally three RCTs14-16 referred to other sur-
geries. When Authors compared coated/uncoated 
sutures for the same surgical procedure, it intro-
duced only a variable (coated suture) in a uniform 
background, an ideal clinical setting with the 
lowest risk of heterogeneity. On the other hand, 
in this case, Authors’ results are related only to a 
specific surgical procedure. If we analyzed trials 
describing different types of surgical procedures, 
clinical variables deriving from such heteroge-
neity of procedures could affect the obtained 
results. Further, it is important that all incisions 
should be classified as clean, clean-contaminated, 
contaminated/dirty and dirty, thus validating the 
effect of TCS to close all type of incisions, not 
in all trials incision contamination was described. 
Meta-analyses by extracting data from multiple 
trials overcome the limits related to the restricted 
sample size of the single clinical trial. Further, 
they perform the quantitative synthesis of data from 
multiple RCTs, thus providing a more comprehen-
sive estimation with greater statistical power. For 
this reason, we analyzed, seven meta-analyses 
investigating the impact of TCSs on SSI rate29-35. 
On the basis of our research, meta-analyses are 
not completely able to restrict the confounding 
effect of the differences and heterogeneities among 
studies and populations. Meta-analyses analyzed 
together with their limitations are summarized in 
Table II. In particular, Chang et al33 published a 
meta-analysis suggesting that the selective use of 
TCSs conveys no protection against postoperative 
SSI. In all of the examined studies, patients un-
dergoing different types of surgery were studied 
(trials on brain, breast, appendix, colorectum, gy-
necological, vascular, cardiac, plastic, abdominal, 
and general surgery were analyzed together). As 
described previously, in this case, different types 
of operations contribute to increase the heteroge-
neity between study populations. Further, not in 
all trials incision contamination was described. 
Validity could not be established for the effect 
of TCSs to close dirty incisions or for operations 
where incision contamination was not described. 
Sandini et al35 selected a specific population of 
patients undergoing elective colorectal resections 
to minimize heterogeneity of class of wound 
contamination and type of operation. They con-
cluded that their findings failed to demonstrate a 
significant protective effect of TCSs on the occur-
rence of SSI after elective colorectal resections.
Meta-analysis Patients (N)/RCTs (N) Type of surgery Limitation Conclusions  
 
Chang WK33, 2012 7 RCTs,  General, Cerebrospinal fluid Small sample size The selective use of TCSs
  836 patients   shunt, Abdominal, Breast,  No stratification of the risk for wound class contamination,  conveys no protection
  (pediatric, adult)  Cardiac, Vascular  type of operation, or organ/apparatus involved.  against postoperative SSI W a n g 
ZX32, 2013 17 RCTs, Abdominal, Breast, Cardiac Only five of the trials clearly defined the diagnostic TCS use has a 30%
  3720 patients   criteria for SSI developed by the CDC criteria.  advantage in reducing SSI risk
  (pediatric, adult)  Consistently significant results in adult patients 
    abdominal surgery, clear or dirty/contaminated surgery; A significant reduction
    in paediatric patients, contaminated/dirty incisions,  in the occurrence of SSI.
    breast or cardiac surgery, such beneficial effect was not clear.
   The quality of included trials is still not fully satisfactory. 
   Not all studies adhered to CDC criteria.
   Different settings of participants and for varying 
    surgical procedures. 
   Insufficient individual patient data.
   Heterogeneity of outcome.  
Edmiston CE Jr31,  13 RCTs, General, Cerebrospinal fluid Selective study parameters were missing from some 31% reduction of risk associated
 2013  3568 patients  shunt, Abdominal, Breast,  of the RCTs elected studies.  with the use of TCSs for
  (pediatric/adult)  Cardiac, Vascular Not all studies adhered to CDC criteria.  prevention of SSIs compared
   Timing, dosing, and agent used for antimicrobial   with non-antimicrobial-coated
    prophylaxis were not standardized.  sutures.
   There was no consistent reporting of other evidence-
    based interventions, such as glycemic control 
    or maintenance normothermia.
   Studies didn’t address adequately the impact of specific 
    risk factors for patients.
Daoud FC30, 2014 15 RCTs General, Cerebrospinal fluid Several trials didn’t use CDC criteria in defying SSI TCSs reduced the risk of SSI by 33%
  4800 patients  shunt, Abdominal, Breast,  incision class.  after clean, clean-contaminated,
  (pediatric/adult)  Cardiac, Vascular   and contaminated surgeries.
Apisarnthanarak A29, 22 RCTs, 7 non-RCTs General, Head/ neck cancer The potential for bias is greater in non-RCTs. TCSs reduced the risk of SSI 
 2015  11942 patients  reconstruction, Vascular, Design, in part, may explain heterogeneity.  by 26% among patients
  (pediatric/adult)  Cardiac, Breast cancer. CDC criteria heterogeneity.  undergoing surgery. This  
   The quality of some of the included studies could not   effect was particularly evident
    be determined with certainty (lack of information,  among those who underwent  
    methodological issues).  abdominal surgery.
Guo J34, 2015 13 RCTs,
 5256 adult patients General, Abdominal, Breast, Authors failed to detect an association between TCSs were associated with lower
   Cardiac, Vascular   coated sutures and reduced risk of SSI for  risk of SSI than uncoated sutures
    non-abdominal procedures.  across all surgeries, for adult patients
Sandini M35, 2016 6 RCTs, Exclusively colon rectal No stratification of the risk for SSI. Findings failed to demonstrate
 2168 adult patients  The quality of included trials is still not fully satisfactory.  a significant protective effect of TCSs
   Heterogeneity among studies.  on the occurrence of SSI after 
     elective colorectal resections.
Table II. Meta-analyses of randomised trials comparing triclosan-coated sutures (TCSs) with uncoated standard sutures for surgical procedures.




In fact, as upon described, even though, trials 
comparing coated/uncoated sutures for only one 
type of surgery provide a more uniform setting, 
on the other hand, they restrict the analysis to 
only one specific type of population. Further, 
there were discrepancies of results even among 
the trials regarding colorectal surgery only18,26, 
probably due to the fact that the composition of 
the colonic microbiota is substantially different 
in different population depending on alimentary 
habit and environmental conditions. Wang et 
al32 extracted data from 3720 surgical patients, 
with more uniform background and less clinical 
heterogeneity, confirming the beneficial effect of 
TCS in SSI prevention. On the other hand, Au-
thors described their meta-analysis limitations, 
consisting of different SSI definition Criteria, 
different surgical procedures and different qual-
ity of the several included RCTs. On the basis 
of our trial results and the heterogeneous find-
ings of the selected meta-analyses, we conclude 
that the question of whether TCSs can reduce 
the occurrence of SSI remains still open. Fu-
ture well-designed RCTs of high methodological 
quality are needed, reporting complete data, 
using CDC criteria in defying SSI together with 
CDC incision class. Our limitations: Similar to 
other systematic reviews, the quality of some 
of the included studies could not be determined 
with certainty due to lack of information pro-
vided, and others had methodological issues 
compromising the overall rigor or quality of the 
studies.
Conclusions
SSIs cause major discomfort for the patient, 
are potentially life-threatening events, prolong 
hospitalization stays and finally increase direct 
and indirect costs with a significant overall finan-
cial burden for any health care system. The main 
additional costs are related to re-operation, extra 
nursing care and interventions, and finally drug 
treatment costs. The indirect costs, due to loss of 
productivity, patient dissatisfaction and litigation, 
and reduced quality of life have been studied less 
extensively. The treatment of SSI can be very 
costly, and the use of antibacterial effect suture 
for wound closure can prevent wound infections 
after surgery, thus reducing SSI rate.
Among the innovative approaches to reduce 
the risk of incision infection is the ability to 
impregnate suture materials with antimicrobial 
substances. In fact, microbial adherence to the 
surface of sutures has been recognized as one 
of the reasons for the development of incision 
infections. 
On the basis of our research, our findings 
suggest that, despite controversial results among 
the clinical studies, the antimicrobial suture was 
effective in decreasing the risk for postoperative 
SSIs in a broad population of patients undergo-
ing surgery. To prevent microbial colonization 
of sutures, in fact, antimicrobial-coated mate-
rials have become available, these are made of 
inert, non-antigenic and safe materials12-24. To 
date, most antimicrobial sutures are coated with 
triclosan. Alternative substances are becoming 
clinically relevant too, such as Chlorhexidine 
(CHS)-coated sutures. CHX is a biguanide an-
tiseptic with antibacterial activity that has been 
in widespread use since the late 1940s. There is 
extensive dental, obstetric, and surgical scrub 
literature on the use of CHX in specialized set-
tings36-38. CHX is poorly absorbed across muco-
sal surfaces and minimally absorbed percutane-
ously; it has been used in several pharmaceutical 
products over the past 30 years for its antiseptic 
properties and safety profile36-45. Only 6 scien-
tific studies36-41 evaluated in vitro CHX-coated 
sutures. They demonstrated that CHX forms an 
inhibition zone around suture material and it is 
effective against the pathogens responsible most 
frequently for SSIs. CHX is positively charged 
and reacts with the negatively charged micro-
bial cell surface, thereby destroying the integ-
rity of the cell membrane. Subsequently, CHX 
penetrates into the cell and causes leakage of 
intracellular components leading to cell death. 
We focused our attention on a recent research 
described by Sethi et al39, who used coated 
suture in order to prevent the colonization of 
periodontal pathogens and to promote inhibition 
of oral biofilm formation. This is a comparative 
evaluation of sutures coated with triclosan and 
CHX. On the basis of Authors’ results, the 
analysis showed maximum biofilm inhibition 
potential with CHX-coated suture followed by 
triclosan-coated suture. In vivo studies, large 
and comparative clinical research trials are nec-
essary to validate the efficacy of CHX-coated 
sutures thus allowing its use in clinical practice.
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